ProfileGDS5678 / 1456057_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 96% 96% 96% 96% 95% 95% 95% 96% 96% 96% 96% 96% 96% 95% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.7411396
GSM967853U87-EV human glioblastoma xenograft - Control 28.9574296
GSM967854U87-EV human glioblastoma xenograft - Control 38.7643496
GSM967855U87-EV human glioblastoma xenograft - Control 48.9422396
GSM967856U87-EV human glioblastoma xenograft - Control 58.5946295
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.2758295
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.3835695
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.7550496
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.6047796
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.7799196
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.6646696
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.9685896
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.7663696
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.6050295